{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-23-000072","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.802278+00:00","generated_at":"2026-06-14T10:45:55.059319+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"COMPASS Pathways co-founder Ekaterina Malievskaia steps down as Chief Innovation Officer, remains on board","bullets":["Dr. Malievskaia will step down as Chief Innovation Officer effective June 16, 2023, by mutual agreement.","She will remain a non-executive director, Class I, with term expiring at 2024 annual meeting.","Executive responsibilities will be assumed by the existing executive team.","She co-founded COMPASS in 2017 and led the phase 2b trial of COMP360 psilocybin for treatment-resistant depression.","Transitioning to non-executive director, she will receive annual cash retainer of $40,000 and equity awards."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-23-000072","json":"https://secwatch.observer/filing/0001816590-23-000072.json","markdown":"https://secwatch.observer/filing/0001816590-23-000072.md","text":"https://secwatch.observer/filing/0001816590-23-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659023000072/0001816590-23-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659023000072/cmps-20230530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:45:55.059319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3220efce8e","claim":"Dr. Ekaterina Malievskaia changed role as Chief Innovation Officer at COMPASS Pathways plc.","evidence_excerpt":"Dr. Malievskaia will step down from her executive role and that her employment agreement will terminate effective June 16, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000181659023000072/0001816590-23-000072-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Innovation Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}